Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sangzhi total alkaloids
- Development stage
- Unknown
- Lead developer
- Beijing Wehand-Bio Pharmaceutical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Sangzhi total alkaloids (SZ-A) is a botanical drug derived from the twigs of *Morus alba* L. (mulberry). Developed by the Institute of Materia Medica, Chinese Academy of Medical Sciences, and Beijing Wehand-Viamin Biotech, it was approved by the NMPA in China in 2020 as the first botanical drug for the treatment of type 2 diabetes mellitus (T2DM). The drug primarily acts as an alpha-glucosidase inhibitor, effectively lowering postprandial blood glucose by inhibiting the breakdown of complex carbohydrates in the small intestine. Its active components include polyhydroxyalkaloids such as 1-deoxynojirimycin (DNJ), fagomine, and 1,4-dideoxy-1,4-imino-D-arabinitol (DAB). Beyond glycemic control, it is currently being evaluated in Phase 4 clinical trials for its efficacy and safety in patients with diabetic nephropathy, focusing on renal function and albuminuria reduction.
- Brand names
- Sangzhi Zong Shengwujian
- Other names
- mulberry twig (sangzhi) alkaloidsMulberry Twig AlkaloidsSangzhi AlkaloidsSangzhi Total Alkaloids
02
Targets
Sucrase-Isomaltase
Beyond the preview
Go deeper on sangzhi total alkaloids.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sangzhi total alkaloids.